Form 4: Adaptive Biotechnologies Insider Trading Activity

Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp, reports significant stock transactions under a Rule 10b5-1 trading plan.

Summary

• Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (ADPT), has reported a series of stock transactions between April 6, 2026, and April 8, 2026.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.
• The filings detail the acquisition and disposition of common stock and stock options.
• Specifically, Rubinstein acquired 14,722 shares of common stock on April 6, 2026, at $7.27 per share, and an additional 14,722 shares on April 7, 2026, and April 8, 2026, also at $7.27 per share.
• Concurrently, Rubinstein disposed of 19,060 shares on April 6, 2026, at a weighted average price between $14.05 and $14.86, and another 19,060 shares on April 7, 2026, at a weighted average price between $13.39 and $13.83.
• Further dispositions occurred on April 8, 2026, including 30,841 shares at a weighted average price between $14.45 and $15.21, and 100 shares at $15.48.
• Derivative security transactions include the acquisition of stock options, with 14,722 options acquired on April 6, 2026, at an exercise price of $7.27, and an additional 14,722 options acquired on April 7, 2026, and April 8, 2026, at the same price.
• On April 8, 2026, 11,881 additional stock options were acquired at an exercise price of $12.14.
• Following these transactions, Rubinstein beneficially owns 434,188 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative filing due to the significant stock sales by a key executive, despite the use of a Rule 10b5-1 plan.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating a pre-determined and structured approach to stock sales, which can mitigate concerns about insider trading based on material non-public information.
• The acquisition of stock options at prices below current market prices (implied by sale prices) could represent a positive long-term incentive for the executive.

Negatives

• Significant disposition of common stock by a key executive (President and COO) could be interpreted negatively by the market, suggesting a lack of confidence in near-term stock appreciation.
• The weighted average sale prices for some transactions are lower than the exercise price of some acquired options, indicating a potential loss on those specific option grants if exercised and sold at those prices.

Risks

• The primary risk is the market's perception of insider selling, which can negatively impact the stock price.
• Potential for further stock sales under the Rule 10b5-1 plan, depending on its terms and market conditions.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The future outlook for the stock depends on the company's performance and market conditions, not directly on this insider transaction report.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
• The reporting person undertakes to provide Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by investors. While a Rule 10b5-1 plan provides a structured framework, significant selling by a top executive can still signal a lack of short-term confidence, especially in the biotechnology sector where stock prices can be volatile and heavily influenced by clinical trial results and regulatory approvals.

Stakeholder Impact

• Shareholders: May view the executive's sales as a negative signal, potentially impacting stock price.
• Employees: May experience concern regarding the company's short-term prospects if executive sales are perceived negatively.
• Management: The transactions are part of a planned strategy, indicating ongoing management of personal investments.

Next Steps

• Continued monitoring of Adaptive Biotechnologies Corp's stock performance and future SEC filings.
• Potential for further transactions under the Rule 10b5-1 plan, if applicable.

Key Dates

Recommendation

The filing reports significant stock sales by a key executive, which is typically a negative signal. However, the sales were conducted under a Rule 10b5-1 plan, which mitigates concerns about opportunistic trading. Without further information on the company's performance or the specific terms of the plan, a 'hold' recommendation is prudent, balancing the insider selling with the structured nature of the transactions.

Keywords

Form 4, Insider Trading, Rule 10b5-1, Adaptive Biotechnologies, ADPT, Stock Options, Common Stock, Executive Transactions, SEC Filing